Neuralstem ALS Clinical Trial Update

Definition

Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS), commonly known as Lou Gehrig's disease, is a progressive neuromuscular disease. ALS is characterized by progressive degeneration of motor nerve cells in the brain (upper motor neurons) and spinal cord (lower motor neurons). Most people who develop ALS are between 40 and 70, although the disease can occur at a younger age. Early symptoms of ALS include stiff muscles, muscle twitches, and gradually increasing weakness and muscle wasting.

Main Digest

Neuralstem, Inc. updated the progress of its ongoing Phase I human clinical trial of the company's spinal cord stem cells in the treatment of ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease) at Emory University in Atlanta, Georgia.

advertisement

The company announced that, after reviewing the safety data from the first nine patients, the trial's Safety Monitoring Board has unanimously approved moving to the last group of ALS patients in this part of the safety trial. These next three patients, all of whom are ambulatory, will each receive ten injections, bilaterally, in the lumbar spinal cord. After this cohort, the FDA will review the trial data to date before approving it to move into the final cohort of patients, who will receive injections in the cervical region of the spinal cord.

"We are delighted that we've advanced to this final cohort of patients in the first part of the safety trial," commented Dr. Eva Feldman, PhD, MD, Principal Investigator of the trial and a consultant to Neuralstem. Dr. Feldman is Director of the A. Alfred Taubman Medical Research Institute and Director of Research of the ALS Clinic at the University of Michigan Health System. "We have been pleased with the smooth progress of the trial thus far, from non-ambulatory to ambulatory patients who have an earlier stage of the disease."

"We are greatly encouraged by the SMB's approval to advance the trial to the final three patients to receive full lumbar injections," said Karl Johe, PhD, Chief Scientific Officer and Chairman of Neuralstem's Board of Directors. "The trial has progressed as expected, and we are deeply indebted to the patients and families who have taken part."

About The Trial

The Phase I trial to evaluate the safety of Neuralstem's spinal cord stem cells in the treatment of ALS, the first FDA-approved ALS stem cell trial, has been underway since January, 2010. The trial plans to enroll up to 18 ALS patients, who will be examined at regular intervals post-surgery.

All of the first six patients treated in the trial were non-ambulatory.

Of these, the first three received five injections each, unilaterally, in the lumbar region of the spinal cord.

The next three patients received ten injections each, bilaterally in the lumbar region.

All remaining trial patients are ambulatory, and therefore represent earlier stages of disease progression.

Of the ambulatory group, the first three patients received five injections each, unilaterally, in the lumbar region.

The next three, which have just been approved, will receive ten injections each, bilaterally, in the lumbar region.

After the required FDA approval, the final six patients in the trial will receive injections in the cervical region.

While the trial is evaluating only the safety of the cells and procedure, it includes exploratory endpoints including attenuation of motor function loss, maintenance of respiratory capacity, and stabilization of patients along the ALS functional rating scale.

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in a FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease, which has been rewarded Orphan Drug Status by the FDA.

In addition to ALS, the company is also targeting major central nervous system diseases, including traumatic spinal cord injury, ischemic spastic paraplegia, and Huntington's disease. The company has also submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury.

Attribution/Source(s):

This quality-reviewed article relating to our Clinical Trial Research section was selected for publishing by the editors of Disabled World due to its likely interest to our disability community readers. Though the content may have been edited for style, clarity, or length, the article "Neuralstem ALS Clinical Trial Update" was originally written by Neuralstem, and published by Disabled-World.com on 2011/02/10 (Updated: 2022/06/06). Should you require further information or clarification, Neuralstem can be contacted at Neuralstem, Inc.. Disabled World makes no warranties or representations in connection therewith.

Share This Information To:
𝕏.com Facebook Reddit

advertisement